TrkA-IN-4

• UNSPSC Description:

  TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC50=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects[1].

• Target Antigen:

  Trk Receptor

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/trka-in-4.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC(OCOC(C1=CN=C(C(NC(C2=CC=C(C(C3=NN(C=C3)C)=C2)C(F)(F)F)=O)=C1)C4=CC=CC=C4)=O)=O

• Molecular Weight:

  538.47

• References & Citations:

  [1]Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  3026111-74-7